Boehringer Ingelheim has partnered with the NCD Alliance, a global network focused on improving health outcomes for everyone. The partnership was announced during the United Nations Global Assembly in New York.
Non-communicable diseases (NCDs), which are not transmitted from person to person, represent a major global health concern. These diseases cause 41 million deaths annually, accounting for 74% of all deaths worldwide. With one in three people living with an NCD and half of the world’s population lacking essential health services, many individuals are not receiving the care they need.
Cardiovascular, Renal, and Metabolic (CRM) diseases, a subset of NCDs, specifically impact the heart, kidneys, and the body’s metabolism. Affecting over a billion people globally, CRM diseases are the leading cause of death worldwide, accounting for up to 20 million deaths annually.
Through this partnership, Boehringer Ingelheim and the NCD Alliance will advocate for stronger health systems to address NCDs and ensure their integration within Universal Health Coverage and primary health care, with a focus on cardiovascular, renal, and metabolic conditions. The partnership will also strengthen evidence and advocacy to address disparities in access to NCD care, ensuring that vulnerable populations and those left behind receive the necessary support.
“This partnership offers a unique opportunity to showcase successful examples of health system strengthening for the NCD response, particularly addressing health equity and reaching underserved communities,” said Katie Dain, CEO of NCD Alliance. “Our goal is to guarantee access to quality care for all, regardless of income or geography”.
Boehringer Ingelheim already assists millions of people worldwide in living longer, healthier lives. Aligned with its sustainability framework, “Sustainable Development for Generations”, Boehringer Ingelheim has committed to expanding NCD healthcare access for 50 million individuals in underserved communities and low- and middle-income countries by 2030.
“This partnership is incredibly timely,” says Médard Schoenmaeckers, Head of Corporate Affairs. “Alongside the NCD Alliance, we are committed to overcoming barriers to quality care. We believe that where you live or how much you earn shouldn’t determine your access to treatment. This collaboration embodies our commitment to improved health systems, reduced disease burden, and ultimately, a transformation of global health.”
Boehringer Ingelheim’s sustainability strategy addresses health equity and well-being across the entire patient care continuum: from pharmaceutical innovation to prevention, healthcare delivery, and tackling equitable access. This strategy is particularly focused on improving the lives of people and animals living in underserved communities. Fostering multi-stakeholder collaboration is a crucial aspect of promoting systemic change.
Boehringer Ingelheim
Boehringer Ingelheim is a biopharmaceutical company dedicated to both human and animal health. As a leading investor in Research and Development, the company focuses on developing innovative therapies for areas with significant unmet medical needs. Independent since its founding in 1885, Boehringer Ingelheim embraces a long-term perspective, integrating sustainability across its entire value chain. Over 53,500 employees serve more than 130 markets to create a healthier, more sustainable, and equitable future. Learn more at .
Intended Audiences Notice
This press release originates from our Corporate Headquarters in Ingelheim, Germany, and aims to provide information about our global business. Please be aware that information regarding the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we operate.